专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08372863B2 Tetrahydro-1H-pyrrolo fused pyridones 有权
标题翻译：四氢-1H-吡咯稠合吡啶酮
公开(公告)号：US08372863B2
公开(公告)日：2013-02-12
申请号：US12919199
申请日：2009-02-11
申请人： Matthew J. Clements , Vincent J. Colandrea , John S. Debenham , Jeffrey J. Hale , Christina B. Madsen-Duggan , Thomas F. Walsh
发明人： Matthew J. Clements , Vincent J. Colandrea , John S. Debenham , Jeffrey J. Hale , Christina B. Madsen-Duggan , Thomas F. Walsh
IPC分类号： A61K31/44 , C07D221/02
CPC分类号： C07D471/04
摘要： The present invention relates to tetrahydro-1H-pyrrolo fused pyridone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
摘要翻译：本发明涉及可用作HIF脯氨酰羟化酶抑制剂治疗贫血和类似病症的四氢-1H-吡咯稠合吡啶酮化合物。

2. 发明申请

US20110009406A1 TETRAHYDRO-1H-PYRROLO FUSED PYRIDONES 有权
标题翻译：四氢-1H-吡咯醇加成的吡啶
公开(公告)号：US20110009406A1
公开(公告)日：2011-01-13
申请号：US12919199
申请日：2009-02-11
申请人： Matthew J. Clements , Vincent J. Colandrea , John S. Debenham , Jeffrey J. Hale , Christina B. Madsen-Duggan , Thomas F. Walsh
发明人： Matthew J. Clements , Vincent J. Colandrea , John S. Debenham , Jeffrey J. Hale , Christina B. Madsen-Duggan , Thomas F. Walsh
IPC分类号： A61K31/5377 , C07D471/04 , A61K31/437 , C07D413/14 , C07D487/04 , A61K31/519 , A61P7/06
CPC分类号： C07D471/04
摘要： The present invention relates to tetrahydro-1H-pyrrolo fused pyridone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
摘要翻译：本发明涉及可用作HIF脯氨酰羟化酶抑制剂治疗贫血和类似病症的四氢-1H-吡咯稠合吡啶酮化合物。

3. 发明授权

US08278304B2 Substituted 4-hydroxypyrimidine-5-carboxamides 有权
标题翻译：取代的4-羟基嘧啶-5-甲酰胺
公开(公告)号：US08278304B2
公开(公告)日：2012-10-02
申请号：US12381468
申请日：2009-03-12
申请人： Matthew J. Clements , John S. Debenham , Jeffrey J. Hale , Christina B. Madsen-Duggan , Thomas F. Walsh
发明人： Matthew J. Clements , John S. Debenham , Jeffrey J. Hale , Christina B. Madsen-Duggan , Thomas F. Walsh
IPC分类号： A61K31/501 , A61K31/4965 , C07D401/06 , C07D239/02
CPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/04 , C07D417/14
摘要： The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
摘要翻译：本发明涉及用作HIF脯氨酰羟化酶抑制剂治疗贫血和类似病症的取代的4-羟基嘧啶-5-甲酰胺。

4. 发明申请

US20080269279A1 Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators 审中-公开
标题翻译：取代的呋喃并[2,3-B]吡啶衍生物作为大麻素-1受体调节剂
公开(公告)号：US20080269279A1
公开(公告)日：2008-10-30
申请号：US12082013
申请日：2008-04-07
申请人： Matthew J. Clements , John S. Debenham , Jeffrey J. Hale , Christina B. Madsen-Duggan , Thomas F. Walsh , Andrey V. Peresypkin , Roy Helmy
发明人： Matthew J. Clements , John S. Debenham , Jeffrey J. Hale , Christina B. Madsen-Duggan , Thomas F. Walsh , Andrey V. Peresypkin , Roy Helmy
IPC分类号： A61K31/4355 , C07D471/04 , A61P25/00 , A61P3/04
CPC分类号： C07D491/048
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.
摘要翻译：结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，阿尔茨海默病，偏头痛，神经病，包括多发性硬化症和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症的中枢作用药物脑血管意外，头部创伤，焦虑障碍，压力，癫痫，帕金森病，运动障碍和精神分裂症。这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻，肝硬化，非酒精性脂肪性肝病（NAFLD ），非酒精性脂肪性肝炎（NASH），以及促进觉醒。

5. 发明授权

US08445680B2 Tetrahydrothieno pyridines 有权
标题翻译：四氢噻吩并吡啶
公开(公告)号：US08445680B2
公开(公告)日：2013-05-21
申请号：US12919190
申请日：2009-02-11
申请人： John S. Debenham , Jeffrey J. Hale , Christina B. Madsen-Duggan , Thomas F. Walsh
发明人： John S. Debenham , Jeffrey J. Hale , Christina B. Madsen-Duggan , Thomas F. Walsh
IPC分类号： C07D495/04 , A61K31/4436
CPC分类号： C07D495/04
摘要： The present invention relates to tetrahydrothienopyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
摘要翻译：本发明涉及用作HIF脯氨酰羟化酶抑制剂治疗贫血和类似病症的四氢噻吩并吡啶化合物。

6. 发明申请

US20110009425A1 TETRAHYDROTHIENO PYRIDINES 有权
标题翻译：四氯乙烯吡啶
公开(公告)号：US20110009425A1
公开(公告)日：2011-01-13
申请号：US12919190
申请日：2009-02-11
申请人： John S. Debenham , Jeffrey J. Hale , Christina B. Madsen-Duggan , Thomas F. Walsh
发明人： John S. Debenham , Jeffrey J. Hale , Christina B. Madsen-Duggan , Thomas F. Walsh
IPC分类号： A61K31/497 , C07D495/04 , A61K31/4365 , C07D401/14 , A61P7/06
CPC分类号： C07D495/04
摘要： The present invention relates to tetrahydrothienopyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
摘要翻译：本发明涉及用作HIF脯氨酰羟化酶抑制剂治疗贫血和类似病症的四氢噻吩并吡啶化合物。

7. 发明申请

US20100029697A1 SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS 审中-公开
标题翻译：取代的吡咯并[3,2-E] [1,2,4]三唑并[4,3-C]吡啶衍生物作为CANNABINOID-1受体调节剂
公开(公告)号：US20100029697A1
公开(公告)日：2010-02-04
申请号：US12529889
申请日：2008-03-24
申请人： John S. Debenham , Christina B. Madsen-Duggan , Jeffrey J. Hale , Thomas F. Walsh
发明人： John S. Debenham , Christina B. Madsen-Duggan , Jeffrey J. Hale , Thomas F. Walsh
IPC分类号： A61K31/519 , C07D471/14 , A61P3/04 , A61P25/00 , A61P25/28 , A61P25/16 , A61P25/06 , A61P1/16 , A61P11/06 , A61P25/30
CPC分类号： C07D487/14
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer s disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.
摘要翻译：结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。本发明的化合物可用作治疗精神病，记忆缺陷症，认知障碍，阿尔茨海默氏病，偏头痛，神经病，包括多发性硬化症和神经 - 巴利综合征的神经炎症性疾病以及病毒性炎症后遗症的中枢作用药物脑炎，脑血管意外和头部创伤，焦虑障碍，压力，癫痫，帕金森病，运动障碍和精神分裂症。这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻，肝硬化，非酒精性脂肪性肝病（NAFLD ），非酒精性脂肪性肝炎（NASH），以及促进觉醒。

8. 发明授权

US07999107B2 Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators 失效
标题翻译：取代的吡喃并[2,3-B]吡啶衍生物作为大麻素-1受体调节剂
公开(公告)号：US07999107B2
公开(公告)日：2011-08-16
申请号：US12009114
申请日：2008-01-16
申请人： John S. Debenham , Jeffrey J. Hale , Pei Huo , Christina B. Madsen-Duggan , Thomas F. Walsh , Lin Yan
发明人： John S. Debenham , Jeffrey J. Hale , Pei Huo , Christina B. Madsen-Duggan , Thomas F. Walsh , Lin Yan
IPC分类号： C07D491/052 , A61K31/436
CPC分类号： C07D491/052 , C07D491/16 , C07D495/16
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, Huntington's disease movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.
摘要翻译：结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，阿尔茨海默病，偏头痛，神经病，包括多发性硬化症和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症的中枢作用药物脑血管意外，头部创伤，焦虑障碍，压力，癫痫，帕金森病，亨廷顿病运动障碍和精神分裂症。这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻，肝硬化，非酒精性脂肪性肝病（NAFLD ），非酒精性脂肪性肝炎（NASH），以及促进觉醒。

9. 发明申请

US20080207666A1 Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators 失效
标题翻译：取代的吡喃并[2,3-B]吡啶衍生物作为大麻素-1受体调节剂
公开(公告)号：US20080207666A1
公开(公告)日：2008-08-28
申请号：US12009114
申请日：2008-01-16
申请人： John S. Debenham , Jeffrey J. Hale , Pei Huo , Christina B. Madsen-Duggan , Thomas F. Walsh , Lin Yan
发明人： John S. Debenham , Jeffrey J. Hale , Pei Huo , Christina B. Madsen-Duggan , Thomas F. Walsh , Lin Yan
IPC分类号： A61K31/527 , C07D471/10 , A61K31/4433 , C07D471/04 , A61P25/28
CPC分类号： C07D491/052 , C07D491/16 , C07D495/16
摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, Huntington's disease movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.
摘要翻译：结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，阿尔茨海默病，偏头痛，神经病，包括多发性硬化症和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症的中枢作用药物脑血管意外，头部创伤，焦虑障碍，压力，癫痫，帕金森病，亨廷顿病运动障碍和精神分裂症。这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻，肝硬化，非酒精性脂肪性肝病（NAFLD ），非酒精性脂肪性肝炎（NASH），以及促进觉醒。

10. 发明申请

US20090239876A1 Substituted 4-Hydroxypyrimidine-5-Carboxamides 有权
标题翻译：取代的4-羟基嘧啶-5-羧酰胺
公开(公告)号：US20090239876A1
公开(公告)日：2009-09-24
申请号：US12381468
申请日：2009-03-12
申请人： Matthew J. Clements , John S. Debenham , Jeffrey J. Hale , Christian B. Madsen-Duggan , Thomas F. Walsh
发明人： Matthew J. Clements , John S. Debenham , Jeffrey J. Hale , Christian B. Madsen-Duggan , Thomas F. Walsh
IPC分类号： A61K31/501 , A61K31/497 , A61K31/506 , C07D403/04 , C07D401/04 , C07D405/14 , C07D415/00 , C07D401/14
CPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/04 , C07D417/14
摘要： The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
摘要翻译：本发明涉及用作HIF脯氨酰羟化酶抑制剂治疗贫血和类似病症的取代的4-羟基嘧啶-5-甲酰胺。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式